Vemurafenib

About

Therapy type: Targeted therapy

Therapy strategy: B-RAF inhibition

Mappings

NCI Thesaurus: Vemurafenib (ncit:C64768)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600E Melanoma Vemurafenib
Sensitivity (+) BRAF p.V600E Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
Sensitivity (+) BRAF p.V600K Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
Sensitivity (+) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600E Melanoma Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Vemurafenib
Sensitivity (+) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Cobimetinib, Vemurafenib
Sensitivity (+) BRAF p.V600E Melanoma Vemurafenib
Sensitivity (+) BRAF p.V600K Melanoma Vemurafenib